Evidence lacking for drug treatment of multiple sclerosis-related cognitive impairment

There was insufficient evidence for cognitive efficacy across the spectrum of pharmacologic agents used in multiple sclerosis. ‘Given the impact of cognitive dysfunction on individuals with MS, it is prudent to explore the potential for cognitive efficacy of available pharmaceuticals,” explained Dr. Genova. “The design of future studies, especially of DMTs, must focus on cognitive outcomes and follow standardized criteria. Randomized, controlled studies with cognition as the primary outcomes will provide clinicians with the information they need to choose optimal treatments for patients.’